First FDA-Approved Gene Therapy Sheets for RDEB Wounds

Zevaskyn (prademagene zamikeracel) is an autologous cell sheet-based gene therapy made from a patient’s own skin cells that have been gene-modified to express functional type VII collagen (C7) and formed into sheets for surgical application onto wounds. On the US Prescribing Information (revised 3/2026) it is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

This is a traditional FDA biologic approval (CBER). The FDA approved STN BL 125807/0 on 28 April 2025. Approval letter issues U.S. License No. 2329 to Abeona Therapeutics, Inc., Cleveland, Ohio. Associated NCT numbers on the letter: NCT01263379, NCT04227106, NCT05708677, and NCT05725018.

Distinct path — not this carton (fact-only): Supportive wound dressings alone, pain management alone, or infection care alone are not this gene-modified autologous sheet carton. Other epidermolysis bullosa subtypes without labelled RDEB wound indication are not this population. Topical or systemic therapies labelled for other EB pathways are not this Abeona sheet lot. Today’s US labelled autologous gene-modified cellular-sheet door for RDEB wounds is Abeona Zevaskyn STN 125807.

Manufactured and distributed by Abeona Therapeutics Inc., 6555 Carnegie Avenue, Cleveland, OH 44103. Commercial access is organised through Qualified Treatment Centers (QTCs) with Abeona Assist patient-navigation support.

Where this is taking place

Commercial labelled door today: United States — FDA-labelled Zevaskyn for RDEB wounds in adults and pediatrics, administered only after two 8 mm punch biopsies (company support framing), manufacturing of patient-specific sheets (~25 days in Abeona Assist materials), shipment to a Qualified Treatment Center, operating-room quality-control release, wound debridement under anesthesia, and surgical fixation of selected sheets with resorbable sutures in a single session. Product / malignancy-sample / AE contact on PI: Abeona Therapeutics 1-844-888-2236. Patient navigation / enrollment: Abeona Assist 1-855-223-6621 (855-ABEONA-1) or MyNavigator@AbeonaAssist.com (hours stated Mon–Fri 9:00am–6:30pm ET on the Assist site, with after-hours support noted). This is a centre-administered autologous gene-therapy surgery conversation — not a retail pharmacy pickup and not a DIY import.

Honesty on US centre readiness: Company materials and the patient site describe an expanding QTC network. Abeona announced activation of University of Florida Health (Gainesville) as the eighth QTC on 16 September 2026. Treat named-centre lists as dynamic — ask Abeona Assist / the treating EB clinician for the current referral path rather than assuming every major hospital already applies Zevaskyn.

Outside the United States: As of this draft, no confirmed Health Canada Notice of Compliance / DIN for Zevaskyn. Do not import on your own. Historical research geography is not the same sentence as a Canadian or other foreign marketing authorisation for your home regulator.

VIITAL — NCT04227106 (ClinicalTrials.gov: COMPLETED) — Multicenter, randomized, intrapatient-controlled Phase 3 study of Zevaskyn vs standard-of-care dressings for matched large chronic RDEB wounds. Letter/PI also cite earlier/related programs NCT01263379 (COMPLETED), NCT05708677 (ENROLLING_BY_INVITATION), and NCT05725018 (ACTIVE_NOT_RECRUITING). Honesty: Labelled commercial access is through QTCs — completed pivotal enrolment is not walk-in research recruitment.

The practical commercial door in the US is an EB / dermatology / wound / genetics team working with a QTC and Abeona Assist to confirm RDEB genetics, map treatable wounds, schedule biopsy and surgery, and arrange payer / travel logistics.

Approval matrix

Access by country

• United States: Ask an EB / dermatology / wound-genetics clinician about referral for FDA-labelled Zevaskyn. Labelled 28 April 2025. Path: confirm RDEB → QTC consult → punch biopsies → manufacturing (25 days per Assist materials) → surgical application of selected sheets (each 41.25 cm²; up to 12) after debridement → leave dressings undisturbed 5–10 days; keep dry until gauze backing falls off (2–3 weeks). Abeona Assist enrollment / navigator: 1-855-223-6621 or MyNavigator@AbeonaAssist.com. Suspected adverse reactions / malignancy-sample instructions: Abeona 1-844-888-2236 or FDA MedWatch 1-800-FDA-1088. No list price or copay dollars in this article. This is US labelled supply through QTCs, not a DIY import.

• Canada: Zevaskyn authorisation not confirmed. Ask the Canadian EB clinic what legal paths exist in Canada when a Canadian Zevaskyn label does not yet exist.

• European Union / United Kingdom / Australia / Japan / other countries: Confirm your local regulator’s current status with the treating centre. A US sheet lot is not a foreign carton. Do not import on your own.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting.

Who is eligible (from the US label)

This is an autologous gene-modified cellular-sheet conversation on the Prescribing Information — not a walk-in ointment, and not established as a geriatric (≥65) study population on the PI.

United States (USPI, revised March 2026):

• Indication: Treatment of wounds in adult and pediatric patients with RDEB.
• Dose: Based on wound surface area. One sheet covers 41.25 cm². Up to 12 sheets may be manufactured and supplied; apply all selected sheets in one surgical session. Do not trim or overlap sheets; do not suture onto healthy intact skin.
• Contraindications: None listed on the USPI.
• Warnings: Hypersensitivity to vancomycin, amikacin, or excipients; RVV-mediated insertional oncogenesis (lifelong malignancy monitoring); infectious-agent transmission risk because manufacturing uses human- and bovine-derived reagents.
• Most common adverse reactions (≥5% in VIITAL): procedural pain (27%), pruritus (9%).
• Pediatrics: Safety/effectiveness supported in the pivotal study including patients aged 6 and 16 years (among mean age 23, range 6–40).
• Geriatrics: Not studied in patients ≥65.
• Manufacturing failure: A second manufacturing attempt may require a repeat biopsy.

Not labelled on sources confirmed for this draft:

• Non-RDEB epidermolysis bullosa subtypes as a catch-all.
• Canadian (and several other) marketing authorisations (not confirmed here).
• Treating completed research enrolment as open commercial trial recruitment.
• Application outside a QTC / manufacturer-coordinated surgical path.

What the pivotal evidence showed (USPI)

Use the USPI for a prescription conversation. Journals are supportive reading.

VIITAL — NCT04227106 (USPI §14):

• 11 patients; 86 wounds randomised as matched pairs (Zevaskyn vs standard-of-care control). Mean age 23 years (range 6–40); wounds open a median 5 years (range 0.5–21).
• ≥50% healing at Month 6 (confirmed ≥2 weeks later): 35/43 (81%) Zevaskyn vs 7/43 (16%) control (p <0.0001).
• Mean pain reduction (Wong-Baker FACES) at Month 6: −3.07 vs −0.90 (p 0.0002).
• Complete healing (re-epithelialization with no drainage/erosion and only minor crusting) at Month 6: 7/43 (16%) vs 0/43 (0%).
• Median sheets received in the safety description: 6 (range 3–6) with 6-month exposure framing.

How to talk with a doctor

Bring this page and ask an EB / dermatology / genetics / wound clinician:

1. “We have genetically confirmed RDEB with chronic wounds. Is labelled US Zevaskyn a fit, and which Qualified Treatment Center would you refer to?”
2. “What is the current Abeona Assist intake step (1-855-223-6621), and how do biopsy, manufacturing, and surgery timing work?”
3. “Which wounds would you prioritise, and what is the immobilisation / dressing plan for 5–10 days after application?”
4. “How will we plan lifelong malignancy surveillance given the retroviral vector warning?”
5. If outside the US: “Has our regulator authorised Zevaskyn, or what legal special-access options exist?”

Who is involved (from primary sources)

• License holder / manufacturer: Abeona Therapeutics Inc., 6555 Carnegie Avenue, Cleveland, OH 44103 — U.S. License 2329 (approval letter / USPI).
• Patient support: Abeona Assist — 1-855-223-6621; MyNavigator@AbeonaAssist.com (company support site).
• Pivotal / related programs: VIITAL NCT04227106; also letter-associated NCT01263379, NCT05708677, NCT05725018.
• Product / AE contact on USPI: Abeona Therapeutics 1-844-888-2236.
• Public QTC expansion example (company press, 16 Sep 2026): University of Florida Health, Gainesville — described as the eighth activated QTC. Confirm the live roster with Abeona Assist / zevaskyn.com rather than treating any single press list as complete forever.

Names and roles above are limited to what appears on the primary sources cited. Contacts not listed on those sources are omitted.

Sources

• FDA approval letter STN BL 125807/0, 28 Apr 2025
• DailyMed / FDA Package Insert — ZEVASKYN (Rev 3/2026)
• ClinicalTrials.gov NCT04227106, NCT01263379, NCT05708677, NCT05725018
• Abeona Assist HCP / patient support materials (enrollment phone, QTC journey framing)
• Abeona press: UF Health QTC activation, 16 Sep 2026

Authorized is not funded. Not medical advice.